Actuate THERAPEUTICS, Inc. (ACTU) intrinsic value & 10-year financials
Actuate THERAPEUTICS, Inc. (ACTU) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.61
- Market cap
- $12.7M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -160.4%
- Free cash flow (FY2025)
- —
ACTU 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$22.2M | -$1.06 | — | — | -560.4% |
| FY2024 | — | -$27.3M | -$3.26 | — | — | 50.6% |
| FY2023 | — | -$24.7M | -$2.87 | — | — | 28.6% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ACTUATE THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ACTUATE THERAPEUTICS, INC. has earned high returns on invested capital, averaging 24.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
ACTUATE THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ACTUATE THERAPEUTICS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.